Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Meletios A Dimopoulos; Antonio Palumbo; Michel Attal; Meral Beksaç; Faith E. Davies; Michel Delforge; Hermann Einsele; Roman Hájek; J-L Harousseau; Francesco Costa; Heinz Ludwig; U-H Mellqvist; Gareth J. Morgan; Jesús F. San Miguel; Sonja Zweegman; Pieter Sonneveld

doi:10.1038/leu.2011.3

Related publications

Article2007

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Meletios A Dimopoulos, Andrew Spencer, Michael Attal, H. Miles Prince, Jean‐Luc Harousseau, Anna Dmoszyńska, Jesús F. San Miguel, Andrzej Hellmann, Thierry Façon, Robin Foà, Alessandro Corso, Zvenyslava Masliak, Marta Olesnyckyj, Zhinuan Yu, John Patin, Jerome B. Zeldis, Robert Knight

Article2014

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Meletios A Dimopoulos, Xavier Leleu, Antonio Palumbo, Philippe Moreau, Michel Delforge, Michèle Cavo, Heinz Ludwig, Gareth J. Morgan, Faith E. Davies, Pieter Sonneveld, Stephen Schey, Sonja Zweegman, Mona Hansson, Katja Weisel, MV Mateos, T. Facon, Jesús F. San Miguel

Article2008

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Discussion(0)

Related publications

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma